More recently, therapeutic blockade of VEGFR2 with the human anti-VEGFR2 monoclonal antibody (ramucirumab), which, based on successful phase III trials [10–12], was approved by the FDA for gastric, non-small cell lung and colon cancers, but did not meaningfully improve important clinical outcomes in a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer [13]. The gene discussed is KDR; the disease is colonic neoplasm.